SAMSUNG-ELECTRONICS
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced two new ISOCELL Vizion sensors — a time-of-flight (ToF) sensor, the ISOCELL Vizion 63D, and a global shutter sensor, the ISOCELL Vizion 931. First introduced in 2020, Samsung’s ISOCELL Vizion lineup includes ToF and global shutter sensors specifically designed to offer visual capabilities across an extensive range of next-generation mobile, commercial and industrial use cases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231219353837/en/
Samsung Unveils Two New ISOCELL Vizion Sensors Tailored for Robotics and XR Applications (Graphic: Business Wire)
“Engineered with state-of-the-art sensor technologies, Samsung’s ISOCELL Vizion 63D and ISOCELL Vizion 931 will be essential in facilitating machine vision for future high-tech applications like robotics and extended reality (XR),” said Haechang Lee, Executive Vice President of the Next Generation Sensor Development Team at Samsung Electronics. “Leveraging our rich history in technological innovation, we are committed to driving the rapidly expanding image sensor market forward.”
ISOCELL Vizion 63D: Tailored for capturing high-resolution 3D images with exceptional detail
Similar to how bats use echolocation to navigate in the dark, ToF sensors measure distance and depth by calculating the time it takes the emitted light to travel to and from an object.
Particularly, Samsung’s ISOCELL Vizion 63D is an indirect ToF (iToF) sensor that measures the phase shift between emitted and reflected light to sense its surroundings in three dimensions. With exceptional accuracy and clarity, the Vizion 63D is ideal for service and industrial robots as well as XR devices and facial authentication where high-resolution and precise depth measuring are crucial.
The ISOCELL Vizion 63D sensor is the industry’s first iToF sensor with an integrated depth-sensing hardware image signal processor (ISP). With this innovative one-chip design, it can precisely capture 3D depth information without the help of another chip, enabling up to a 40% reduction in system power consumption compared to its predecessor. The sensor can also process images at up to 60 frames per second in QVGA resolution (320x240), which is a high-demand display resolution used in commercial and industrial markets.
Based on the industry’s smallest 3.5㎛ pixel size in iToF sensors, the ISOCELL Vizion 63D achieves high Video Graphics Array (VGA) resolution (640x480) within a 1/6.4” optical format, making it an ideal fit for compact, on-the-go devices.
Thanks to backside scattering technology (BST) that enhances light absorption, the Vizion 63D sensor boasts the highest level of quantum efficiency in the industry, reaching 38% at an infrared light wavelength of 940 nanometers (nm). This enables enhanced light sensitivity and reduced noise, resulting in sharper image quality with minimal motion blur.
Moreover, the ISOCELL Vizion 63D supports both flood (high-resolution at short-range) and spot (long-range) lighting modes, significantly extending its measurable distance range from its predecessor’s five meters to 10.
ISOCELL Vizion 931: Optimized for capturing dynamic movements without distortion
The ISOCELL Vizion 931 is a global shutter image sensor tailored for capturing rapid movements without the “jello effect”. Unlike rolling shutter sensors that scan the scene line by line from top to bottom in a “rolling” manner, global shutter sensors capture the entire scene at once or “globally,” similar to how human eyes see. This allows the ISOCELL Vizion 931 to capture sharp, undistorted images of moving objects, making it well-suited for motion-tracking in XR devices, gaming systems, service and logistics robots as well as drones.
Designed in a one-to-one ratio VGA resolution (640 x 640) that packs more pixels in a smaller form factor, the ISOCELL Vizion 931 is optimal for iris recognition, eye tracking as well as facial and gesture detection in head-mounted display devices like XR headsets.
The ISOCELL Vizion 931 also achieves the industry’s highest level of quantum efficiency, delivering an impressive 60% at 850nm infrared light wavelength. This feat was made possible by incorporating Front Deep Trench Isolation (FDTI) which places an insulation layer between pixels to maximize light absorption, in addition to the BST method used in the ISOCELL Vizion 63D.
The Vizion 931 supports multi-drop that can seamlessly connect up to four cameras to the application processor using a single wire. With minimal wiring required, the sensor provides greater design flexibility for device manufactures.
Samsung ISOCELL Vizion 63D and ISOCELL Vizion 931 sensors are currently sampling to OEMs worldwide.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231219353837/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy7.11.2025 17:00:00 CET | Press release
− Phase 1b, Open-Label Study Follow Up Shows Stable Kidney Function (eGFR) in Patients Treated with Investigational Mezagitamab Through Week 96 – 18 Months After Last Dose1− Rapid Reductions in Proteinuria and Serum Gd-IgA1 Levels Were Sustained Through Week 961− No Serious Adverse Events or Opportunistic Infections Were Observed Through Week 961− Takeda Initiated Pivotal Phase 3 Clinical Trials Evaluating Mezagitamab in Primary IgA Nephropathy and Immune Thrombocytopenia with Patient Enrollment Ongoing Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin A (IgA) nephropathy. Data from the study showed that kidney function (eGFR) remained stable in patients with IgA nephropathy through Week 96 – up to 18 months after the last mezagitamab dose.1 The results were presented at the American Society o
Oremus Corporate Services Expands into Europe with Launch in Finland7.11.2025 16:23:00 CET | Press release
CEO, Lalit Ananth Chawla, to Attend Slush 2025 in Helsinki Oremus Corporate Services Private Limited, a multinational Finance and Accounting Advisory firm having its offices in the USA, India and the UK, has announced the extension of its services to Finland, marking the company’s foray into the European market. With over two decades of expertise in accounting, payroll, tax compliance, and advisory services, Oremus has earned trust as a technology-driven finance partner serving clients across geographies. Oremus is an ISAE 3402, ISO 27001, GDPR & DPDP Compliant Company, adhering to International Quality and Security Standards. “Finland isn’t just a new market for us — it’s the gateway to meaningful, growth-driven partnerships across Europe”. said Lalit Ananth Chawla, CEO of Oremus. Having established a strong reputation for delivering reliable Accounting and Advisory solutions to scale-ups and growing businesses, we seek to collaborate with like-minded firms and investors to build a tr
Experian Named a Leader in IDC MarketScape: Worldwide Identity Verification in Financial Services 2025 Vendor Assessment7.11.2025 15:00:00 CET | Press release
Advanced fraud prevention, multi-layered verification and innovative data-driven security solutions are core to Experian’s Ascend Platform™ Experian today announced it has been named a leader in the IDC MarketScape: Worldwide Identity Verification in Financial Services 2025 Vendor Assessment (doc # US52985325, September 2025). The report evaluates vendors on the depth and breadth of their identity verification capabilities and on how effectively they align with current and future customer needs. The IDC MarketScape methodology for this assessment involved two key measures of success: capabilities that reflect Experian’s current menu of services and how well aligned they are to its customer needs as well as strategies that indicate how well Experian’s future strategy aligns with what customers will require in three to five years. “This assessment offers a 360-degree view of our identity-verification solutions, and we’re very proud to be recognized as a leader,” said Keith Little, Presid
Rachelle Alexis Lim is appointed CEO of MultiSafepay as the Company Aims to Better Serve European SMEs with Innovative Solutions7.11.2025 14:12:00 CET | Press release
Digital payments veteran Rachelle Alexis Lim now spearheads MultiSafepay’s operational strategy as it brings its innovative omnichannel payment platform to businesses of all sizes across Europe, driving inclusive growth for SMEs. Founder, Olaf Geurs, who has led MultiSafepay for nearly three decades will remain Chief Technology Officer and hold his position on the board of directors. In this role he will remain instrumental to driving innovation. Since the start of its strategic partnership with global payment and digitisation provider Antom, MultiSafepay's transaction volume has nearly doubled, and its merchant base has increased by over a quarter. MultiSafepay, a leading European payment service provider, today announces that Rachelle Alexis Lim has been appointed as the new Chief Executive Officer (CEO) of MultiSafepay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107657130/en/ Rachelle Alexis Lim is appointed CEO of
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie7.11.2025 13:30:00 CET | Press release
Net proceeds will be applied to debt reduction, advancing Organon’s ongoing deleveraging effortsPositions Organon for future investment in growth opportunities with a focus on women’s health biopharma and other strategic prioritiesLaborie’s capabilities in medical technology will facilitate broader access to JADA for more mothers Organon (NYSE: OGN), (“Organon” or “the Company”) a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement with Laborie Medical Technologies Corp. (“Laborie”), a leading diagnostic and therapeutic medical technology company, for them to acquire the JADA System. The transaction, valued at up to $465 million, is comprised of $440 million to be paid at closing, subject to certain closing adjustments, and a potential payment of up to $25 million subject to the achievement of certain 2026 revenue targets. Approximately 100 employees are expected to transf
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom